NASDAQ:AUPH Aurinia Pharmaceuticals (AUPH) Stock Forecast, Price & News $10.41 -0.09 (-0.86%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$10.31▼$10.5550-Day Range$8.96▼$11.6952-Week Range$4.07▼$12.72Volume1.28 million shsAverage Volume3.20 million shsMarket Capitalization$1.49 billionP/E RatioN/ADividend YieldN/APrice Target$13.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aurinia Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside24.9% Upside$13.00 Price TargetShort InterestHealthy10.85% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.66Based on 2 Articles This WeekInsider TradingSelling Shares$101,211 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.71) to ($0.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.74 out of 5 starsMedical Sector785th out of 981 stocksPharmaceutical Preparations Industry384th out of 473 stocks 2.4 Analyst's Opinion Consensus RatingAurinia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.00, Aurinia Pharmaceuticals has a forecasted upside of 24.9% from its current price of $10.41.Amount of Analyst CoverageAurinia Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted10.85% of the outstanding shares of Aurinia Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAurinia Pharmaceuticals has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Aurinia Pharmaceuticals has recently decreased by 7.12%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAurinia Pharmaceuticals does not currently pay a dividend.Dividend GrowthAurinia Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AUPH. Previous Next 2.6 News and Social Media Coverage News SentimentAurinia Pharmaceuticals has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aurinia Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 10 people have searched for AUPH on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows8 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aurinia Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $101,211.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Aurinia Pharmaceuticals is held by insiders.Percentage Held by Institutions40.36% of the stock of Aurinia Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aurinia Pharmaceuticals are expected to grow in the coming year, from ($0.71) to ($0.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aurinia Pharmaceuticals is -15.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aurinia Pharmaceuticals is -15.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAurinia Pharmaceuticals has a P/B Ratio of 3.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aurinia Pharmaceuticals (NASDAQ:AUPH) StockAurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.Read More Receive AUPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AUPH Stock News HeadlinesJune 6, 2023 | finance.yahoo.comAurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Shares Lagging The Industry But So Is The BusinessJune 1, 2023 | finance.yahoo.comLUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids AloneJune 8, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 26, 2023 | finance.yahoo.comAurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired EmployeesMay 25, 2023 | americanbankingnews.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Director Sells $98,333.58 in StockMay 25, 2023 | americanbankingnews.comDavid R.W. Jayne Sells 8,733 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) StockMay 23, 2023 | finance.yahoo.comAurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Shift From Loss To ProfitMay 22, 2023 | seekingalpha.comAurinia: Despite Milder Shareholder Vote, A Bid To Sell Is Still Not OverJune 8, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 18, 2023 | americanbankingnews.comAurinia Pharmaceuticals (NASDAQ:AUPH) Earns Hold Rating from Analysts at StockNews.comMay 17, 2023 | seekingalpha.comAurinia Pharmaceuticals gains as two board members resign amid holder voteMay 17, 2023 | finance.yahoo.comAurinia Announces 2023 Annual General Meeting ResultsMay 11, 2023 | msn.comAurinia Pharma's largest holder to oppose seven director nominationsMay 11, 2023 | finance.yahoo.comHere's Why Aurinia Pharmaceuticals (AUPH) is a Great Momentum Stock to BuyMay 11, 2023 | finance.yahoo.comMKT Capital Comments on Aurinia’s Largest Shareholder’s Plans to WITHHOLD Support for the Majority of the Board at the 2023 Annual MeetingMay 4, 2023 | seekingalpha.comAurinia Pharmaceuticals Inc. (AUPH) Q1 2023 Earnings Call TranscriptMay 4, 2023 | americanbankingnews.comAurinia Pharmaceuticals (NASDAQ:AUPH) PT Raised to $13.00May 3, 2023 | msn.comHC Wainwright & Co. Reiterates Aurinia Pharmaceuticals (AUPH) Buy RecommendationMay 3, 2023 | finanznachrichten.deAurinia Pharmaceuticals Inc.: Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS (Voclosporin) For Adults with Active Lupus NephritisMay 3, 2023 | finance.yahoo.comAurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus NephritisMay 3, 2023 | americanbankingnews.comAurinia Pharmaceuticals (AUPH) to Release Earnings on ThursdayMay 2, 2023 | finance.yahoo.comISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote "FOR" ALL Company Director Nominees at 2023 Annual General MeetingMay 2, 2023 | finance.yahoo.comAurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)April 28, 2023 | finance.yahoo.comGlass Lewis Recommends Aurinia Shareholders Vote "FOR" ALL Company Director Nominees at 2023 Annual MeetingApril 26, 2023 | finance.yahoo.com3 Biotechs That Might Get Bought Out in 2023April 26, 2023 | americanbankingnews.comAurinia Pharmaceuticals (NASDAQ:AUPH) Shares Up 4.2%April 26, 2023 | americanbankingnews.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesSee More Headlines AUPH Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AUPH Company Calendar Last Earnings5/04/2023Today6/08/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AUPH CUSIPN/A CIK1600620 Webwww.auriniapharma.com Phone250-708-4272Fax250-744-2498Employees300Year FoundedN/APrice Target and Rating Average Stock Price Forecast$13.00 High Stock Price Forecast$14.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+24.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-108,180,000.00 Net Margins-65.90% Pretax Margin-64.37% Return on Equity-23.56% Return on Assets-20.44% Debt Debt-to-Equity RatioN/A Current Ratio10.08 Quick Ratio9.32 Sales & Book Value Annual Sales$134.03 million Price / Sales11.13 Cash FlowN/A Price / Cash FlowN/A Book Value$2.85 per share Price / Book3.66Miscellaneous Outstanding Shares143,030,000Free Float136,884,000Market Cap$1.49 billion OptionableOptionable Beta1.18 Key ExecutivesMr. Peter S. Greenleaf M.B.A. (Age 53)Pres, CEO & Director Comp: $1.24MMr. Joseph M. Miller CPA (Age 49)Chief Financial Officer Comp: $710.03kMr. Matthew Maxwell Donley M.B.A. (Age 54)Exec. VP of Operations & Strategy Comp: $730.21kMr. Stephen P. Robertson (Age 41)Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer Comp: $722.4kMs. DeDe SheelVP of Investor RelationMr. Chris HaysVP of MarketingMr. Fran LynchVP of SalesMr. Michael R. Martin (Age 51)Chief Bus. Officer Ms. Sue EvansHead of Regulatory AffairsMr. Scott HabigChief Commercial OfficerMore ExecutivesKey CompetitorsSyndax PharmaceuticalsNASDAQ:SNDXZentalis PharmaceuticalsNASDAQ:ZNTLAgios PharmaceuticalsNASDAQ:AGIODynavax TechnologiesNASDAQ:DVAX89bioNASDAQ:ETNBView All CompetitorsInsiders & InstitutionsLevel Four Advisory Services LLCBought 239,000 shares on 6/5/2023Ownership: 0.175%Prelude Capital Management LLCBought 15,622 shares on 6/1/2023Ownership: 0.011%ProShare Advisors LLCSold 3,341 shares on 5/26/2023Ownership: 0.018%David R.W. JayneSold 8,733 sharesTotal: $98,333.58 ($11.26/share)Joseph P HaganSold 272 sharesTotal: $2,877.76 ($10.58/share)View All Insider TransactionsView All Institutional Transactions AUPH Stock - Frequently Asked Questions Should I buy or sell Aurinia Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AUPH shares. View AUPH analyst ratings or view top-rated stocks. What is Aurinia Pharmaceuticals' stock price forecast for 2023? 4 brokers have issued 1 year target prices for Aurinia Pharmaceuticals' stock. Their AUPH share price forecasts range from $12.00 to $14.00. On average, they predict the company's stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 24.6% from the stock's current price. View analysts price targets for AUPH or view top-rated stocks among Wall Street analysts. How have AUPH shares performed in 2023? Aurinia Pharmaceuticals' stock was trading at $4.32 at the beginning of 2023. Since then, AUPH stock has increased by 141.4% and is now trading at $10.43. View the best growth stocks for 2023 here. Are investors shorting Aurinia Pharmaceuticals? Aurinia Pharmaceuticals saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 15,520,000 shares, a decrease of 7.1% from the April 30th total of 16,710,000 shares. Based on an average daily trading volume, of 3,110,000 shares, the days-to-cover ratio is presently 5.0 days. View Aurinia Pharmaceuticals' Short Interest. When is Aurinia Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our AUPH earnings forecast. How were Aurinia Pharmaceuticals' earnings last quarter? Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) issued its earnings results on Thursday, May, 4th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05. The biotechnology company earned $34.41 million during the quarter, compared to analyst estimates of $28.12 million. Aurinia Pharmaceuticals had a negative net margin of 65.90% and a negative trailing twelve-month return on equity of 23.56%. The firm's revenue for the quarter was up 59.1% on a year-over-year basis. During the same period last year, the company earned ($0.27) EPS. What ETFs hold Aurinia Pharmaceuticals' stock? ETFs with the largest weight of Aurinia Pharmaceuticals (NASDAQ:AUPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB), What guidance has Aurinia Pharmaceuticals issued on next quarter's earnings? Aurinia Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $135.00 million-$155.00 million, compared to the consensus revenue estimate of $142.68 million. What other stocks do shareholders of Aurinia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY). What is Aurinia Pharmaceuticals' stock symbol? Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH." Who are Aurinia Pharmaceuticals' major shareholders? Aurinia Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.53%), Armistice Capital LLC (2.92%), State Street Corp (1.80%), Renaissance Technologies LLC (1.11%), Geode Capital Management LLC (0.93%) and Balyasny Asset Management L.P. (0.92%). Insiders that own company stock include David RW Jayne, George M Milne Jr, Jill Leversage, Joseph M Miller, Joseph P Hagan, Matthew Maxwell Donley, Michael Robert Martin, Neil Solomons, Peter Greenleaf, Robert Bindert Huizinga and Stephen P Robertson. View institutional ownership trends. How do I buy shares of Aurinia Pharmaceuticals? Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aurinia Pharmaceuticals' stock price today? One share of AUPH stock can currently be purchased for approximately $10.43. How much money does Aurinia Pharmaceuticals make? Aurinia Pharmaceuticals (NASDAQ:AUPH) has a market capitalization of $1.49 billion and generates $134.03 million in revenue each year. The biotechnology company earns $-108,180,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis. How many employees does Aurinia Pharmaceuticals have? The company employs 300 workers across the globe. How can I contact Aurinia Pharmaceuticals? Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The official website for the company is www.auriniapharma.com. The biotechnology company can be reached via phone at 250-708-4272, via email at ir@auriniapharma.com, or via fax at 250-744-2498. This page (NASDAQ:AUPH) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.